NASDAQ:SGMT Sagimet Biosciences (SGMT) Stock Price, News & Analysis $8.73 -0.32 (-3.54%) Closing price 04:00 PM EasternExtended Trading$8.91 +0.18 (+2.05%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sagimet Biosciences Stock (NASDAQ:SGMT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sagimet Biosciences alerts:Sign Up Key Stats Today's Range$8.71▼$9.3050-Day Range$3.49▼$10.2452-Week Range$1.73▼$11.41Volume331,606 shsAverage Volume1.12 million shsMarket Capitalization$267.75 millionP/E RatioN/ADividend YieldN/APrice Target$26.33Consensus RatingBuy Company Overview Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Read More Sagimet Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreSGMT MarketRank™: Sagimet Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 351st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSagimet Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSagimet Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Sagimet Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Sagimet Biosciences are expected to decrease in the coming year, from ($1.60) to ($4.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sagimet Biosciences is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sagimet Biosciences is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSagimet Biosciences has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sagimet Biosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.22% of the float of Sagimet Biosciences has been sold short.Short Interest Ratio / Days to CoverSagimet Biosciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sagimet Biosciences has recently decreased by 6.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSagimet Biosciences does not currently pay a dividend.Dividend GrowthSagimet Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.22% of the float of Sagimet Biosciences has been sold short.Short Interest Ratio / Days to CoverSagimet Biosciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sagimet Biosciences has recently decreased by 6.89%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.72 News SentimentSagimet Biosciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sagimet Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for SGMT on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sagimet Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $771,805.00 in company stock.Percentage Held by Insiders14.70% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sagimet Biosciences' insider trading history. Receive SGMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sagimet Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMT Stock News HeadlinesInsider Selling: Sagimet Biosciences Inc. (NASDAQ:SGMT) Insider Sells 8,277 Shares of StockJuly 24, 2025 | insidertrades.comSagimet Biosciences Inc. to Participate in Canaccord Genuity 45th Annual Growth Conference on August 13, 2025August 5 at 7:19 AM | quiverquant.comQFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft. But one controversial analyst, known for predicting the collapses of Fannie Mae, GM, and others, is issuing a serious warning. He believes Nvidia’s rise has masked a dangerous flaw—and that the stock could fall 50% or more from current levels.August 8 at 2:00 AM | Porter & Company (Ad)Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 5 at 7:00 AM | globenewswire.comAnalysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $26.83July 29, 2025 | americanbankingnews.comSagimet gains as Canaccord Genuity starts with Buy on potential against MASHJuly 24, 2025 | msn.comWe Think Sagimet Biosciences (NASDAQ:SGMT) Can Afford To Drive Business GrowthJuly 16, 2025 | finance.yahoo.comSGMT Sagimet Biosciences Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comSee More Headlines SGMT Stock Analysis - Frequently Asked Questions How have SGMT shares performed this year? Sagimet Biosciences' stock was trading at $4.50 at the start of the year. Since then, SGMT shares have increased by 95.0% and is now trading at $8.7740. How were Sagimet Biosciences' earnings last quarter? Sagimet Biosciences Inc. (NASDAQ:SGMT) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.23. When did Sagimet Biosciences IPO? Sagimet Biosciences (SGMT) raised $85 million in an IPO on Friday, July 14th 2023. The company issued 5,312,500 shares at a price of $16.00 per share. Who are Sagimet Biosciences' major shareholders? Sagimet Biosciences' top institutional shareholders include Geode Capital Management LLC (0.87%), FNY Investment Advisers LLC (0.28%), Dumac Inc. (0.24%) and Abacus Planning Group Inc. (0.10%). Insiders that own company stock include Enterprise Associates 13 L New, David Happel, Elizabeth Rozek, George Kemble, Eduardo Bruno Martins and Beth C Seidenberg. View institutional ownership trends. How do I buy shares of Sagimet Biosciences? Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sagimet Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sagimet Biosciences investors own include XPeng (XPEV), Iovance Biotherapeutics (IOVA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Tenet Healthcare (THC) and Urogen Pharma (URGN). Company Calendar Last Earnings5/08/2025Today8/08/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SGMT CIK1400118 Websagimet.com Phone650-561-8600FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Price Target for Sagimet Biosciences$26.33 High Price Target$32.00 Low Price Target$12.00 Potential Upside/Downside+198.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.57 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.21% Return on Assets-34.09% Debt Debt-to-Equity RatioN/A Current Ratio20.34 Quick Ratio20.34 Sales & Book Value Annual Sales$2 million Price / Sales135.41 Cash FlowN/A Price / Cash FlowN/A Book Value$5.08 per share Price / Book1.74Miscellaneous Outstanding Shares30,670,000Free Float26,166,000Market Cap$270.82 million OptionableOptionable Beta3.37 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:SGMT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 While the market chops sideways and headlines dominate the news cycle, a small group of traders is quietly tak...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.